Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
The Lancet. Child & Adolescent Health|January 24, 2026
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Avy Violari, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 2016
Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory diseaseQing Zhou, Xiaomin Yu, Erkan Demirkaya, et al.
Critical Care Medicine|October 6, 2021
Criteria for Pediatric Sepsis-A Systematic Review and Meta-Analysis by the Pediatric Sepsis Definition TaskforceKusum Menon, Luregn J Schlapbach, Samuel Akech, et al.
Critical Care (London, England)|June 2, 2018
Mortality and morbidity in community-acquired sepsis in European pediatric intensive care units: a prospective cohort study from the European Childhood Life-threatening Infectious Disease Study (EUCLIDS)Navin P Boeddha, Luregn J Schlapbach, Gertjan J Driessen, et al.
Frontiers in Medicine|November 16, 2020
Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid)Bahaa Abu-Raya, Giovanni Battista Migliori, Miguel O'Ryan, et al.
Scientific Reports|November 3, 2016
Natural resistance to Meningococcal Disease related to CFH loci: Meta-analysis of genome-wide association studiesFederico Martinón-Torres, Eileen Png, Chiea Chuen Khor, et al.
The New England Journal of Medicine|March 9, 2022
Shorter Treatment for Nonsevere Tuberculosis in African and Indian ChildrenAnna Turkova, Genevieve H Wills, Eric Wobudeya, et al.
The Lancet. Child & Adolescent Health|June 29, 2020
COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort studyFlorian Götzinger, Begoña Santiago-García, Antoni Noguera-Julián, et al.
Eclinicalmedicine|June 12, 2023
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trialAlexandra Compagnucci, Man K Chan, Yacine Saïdi, et al.
The New England Journal of Medicine|December 29, 2021
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in ChildrenAnna Turkova, Ellen White, Hilda A Mujuru, et al.
Pageof 13